

Substitute for 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/529,850
				Filing Date	03-31-2005
				First Named Inventor	Hank F. Kung
				Art Unit	1618
Examiner Name	Dameron Levest Jones				
Sheet	1	of	2	Attorney Docket Number	UPDI-0154

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), Volume-issue Number(s), publisher, city and/or country where published.	T	
	1	McGivan, J.D. et al., "The transport of glutamine into mammalian cells," <i>Frontiers in Bioscience</i> , Jan. 1, 2007, 12, 874-882		
	2	Ashburn, T.T. et al., "Amyloid probes based on Congo Red distinguish between fibrils comprising different peptides," <i>Chem. Biol.</i> 3:351-358 (1996)		
	3	Berge S.M. et al., "Pharmaceutical Salts," <i>J. Pharm. Sci.</i> 66:1 19 (1977)		
	4	Elhaddaoui, A. et al., "Competition of congo red and thioflavin S binding to amyloid sites in Alzheimer's diseased tissue," <i>Biospectroscopy</i> 1:351-356 (1995)		
	5	Findeis, M.A., "Approaches to discovery and characterization of inhibitors of amyloid β -peptide polymerization," <i>Biochimica et Biophysica Acta</i> 1502:76-84, 2000		
	6	Ginsberg, S. D., et al., "Molecular Pathology of Alzheimer's Disease and Related Disorders," in <i>Cerebral Cortex: Neurodegenerative and Age-related Changes in Structure and Function of Cerebral Cortex</i> , Kluwer Academic/Plenum, NY (1999), pp. 603-654		
	7	Golde, T.E. et al., "Biochemical detection of A β isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease," <i>Biochimica et Biophysica Acta</i> 1502:172-187 (2000)		
	8	Han, G. et al., "Technetium Complexes for the Quantitation of Brain Amyloid," <i>J. Am. Chem. Soc.</i> 118:4506-4507 (1996)		
	9	Klunk, W.E. et al., "Small-molecule beta-amyloid probes which distinguish homogenates of Alzheimer's and control brains," <i>Biol Psychiatry</i> 35:627 (1994)		
	10	Klunk, W.E. et al., "Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation," <i>J. Histochem. Cytochem.</i> 37:1273-1281 (1989)		
	11	Klunk, W.E. et al., "Chrysamine-G Binding to Alzheimer and Control Brain: Autopsy Study of a New Amyloid Probe," <i>Neurobiol. Aging</i> 16:541-548 (1995)		
	12	Klunk, W.E. et al., "Staining of AD and Tg2576 mouse brain with X-34, a highly fluorescent derivative of chrysamine G and a potential in vivo probe for β -sheet fibrils," <i>Abstr. Soc. Neurosci.</i> 23:1638, Abstract No. 636.12, Society for Neuroscience (1997)		
	13	Kuner, P. et al., "Controlling Polymerization of β -Amyloid and Prion-derived Peptides with Synthetic Small Molecule Ligands," <i>J. Biol. Chem.</i> 275:1673-1678 (Jan. 2000)		

Examiner Signature	/D. Jones/	Date Considered	12/23/08
--------------------	------------	-----------------	----------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DJ/

Substitute for 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/529,850
				Filing Date	03-31-2005
				First Named Inventor	Hank F. Kung
				Art Unit	1618
Examiner Name	Dameron Levest Jones				
Sheet	2	of	2	Attorney Docket Number	UPDI-0154

NON PATENT LITERATURE DOCUMENTS			
	14	Lorenzo, A. et al., "Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red," Proc. Natl. Acad. Sci. U.S.A. 91:12243-12247 (1994)	
	15	Mathis, C.A. et al., "Synthesis of a Lipophilic Radioiodinated Ligand with High Affinity to Amyloid Protein in Alzheimer's Disease Brain Tissue," Proc. XIIth Intl. Symp. Radiopharm. Chem., Uppsala, Sweden:94-95 (1997)	
	16	Moore, C.L. et al., "Difluoro ketone peptidomimetics suggest a large S1 pocket for Alzheimer's gamma-secretase: implications for inhibitor design," J. Med. Chem. 43:3434-3442 (2000)	
	17	Näslund, J. et al., "Correlation Between Elevated Levels of Amyloid β -Peptide in the Brain and Cognitive Decline," JAMA 283:1571-1577, American Medical Association (Mar. 2000).	
	18	Selkoe, D. J., "Biology of β -amyloid Precursor Protein and the Mechanism of Alzheimer's Disease," <i>Alzheimer's Disease</i> , Lippincot Williams & Wilkins, Philadelphia, PA (1999), pp. 293-310	
	19	Selkoe, D.J., "The Origins of Alzheimer Disease. A is for Amyloid," J. Am. Med. Assoc. 283:1615-1617 (2000)	
	20	Skovronsky, D.M. et al., " β -Secretase revealed: starting gate for race to novel therapies for Alzheimer's disease," Trends Pharmacol. Sci. 21:161-163 (2000)	
	21	Vassar, R. et al., " β -Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE," Science 286:735-741, 1999	
	22	Vogelsberg-Ragaglia, V., et al., "Cell Biology of Tau and Cytoskeletal Pathology in Alzheimer's Disease," <i>Alzheimer's Disease</i> , Lippincot, Williams & Wilkins, Philadelphia, PA (1999), pp. 359-372	
	23	Wolfe, M.S. et al., "A substrate-based difluoro ketone selectively inhibits Alzheimer's gamma-secretase activity," J. Med. Chem. 41:6-9, 1998	
	24	Xia, W. et al., "Presenilin complexes with the C-terminal fragments of amyloid precursor protein at the sites of amyloid beta-protein generation," J. Proc. Natl. Acad. Sci. U.S.A. 97:9299-9304, (2000)	
	25	Zhen, W. et al., "Synthesis and amyloid binding properties of rhenium complexes: preliminary progress toward a reagent for SPECT imaging of Alzheimer's disease brain," J. Med. Chem. 42:2805-2815 (1999)	

Examiner Signature	/D. Jones/	Date Considered	12/23/08
--------------------	------------	-----------------	----------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DJ/